SCI时时刷

search
+
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
Diagnosing post-transplant lymphoproliferative disorder (PTLD) is challenging and often requires invasive procedures. Anal...
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics
Lipid metabolic reprogramming is an emerging hallmark of cancer. In order to sustain uncontrolled proliferation and surviv...
CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
Pancreatic cancer lacks effective therapy. Here, we reported two metastatic pancreatic cancer patients administrated with ...
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment follo...
Recent advances in targeted strategies for triple-negative breast cancer
Recent advances in targeted strategies for triple-negative breast cancer
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor...
Advances in single-cell RNA sequencing and its applications in cancer research
Advances in single-cell RNA sequencing and its applications in cancer research
Cancers are a group of heterogeneous diseases characterized by the acquisition of functional capabilities during the trans...
Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all NHLs and characterized by over...
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
About half of AML patients achieving complete remission (CR) display measurable residual disease (MRD) and eventually rela...
Challenges and new technologies in adoptive cell therapy
Challenges and new technologies in adoptive cell therapy
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-infiltrating lymphocytes to th...
Retraction Note: HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression
Retraction Note: HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, whi...
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Recently, therapeutic antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1) have exerted potent antican...
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
Immunotherapy has revolutionized cancer treatment, but currently, immuno-oncology agents have not been approved for patien...
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated mult...
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × ...
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia
TP53 mutations (TP53MT) occur in diverse genomic configurations. Particularly, biallelic inactivation is associated with p...
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting
RNA modification has recently become a significant process of gene regulation, and the methyltransferase-like (METTL) fami...
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma...
Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions
Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions
NEDDylation, a post-translational modification through three-step enzymatic cascades, plays crucial roles in the regulatio...
Hyperhomocysteinemia potentiates megakaryocyte differentiation and thrombopoiesis via GH-PI3K-Akt axis
Hyperhomocysteinemia potentiates megakaryocyte differentiation and thrombopoiesis via GH-PI3K-Akt axis
Hyperhomocysteinemia (HHcy) is closely associated with thrombotic diseases such as myocardial infarction and stroke. Enhan...
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell matur...
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to the...
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, whi...
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Immune cell engagers are engineered antibodies with at least one arm binding a tumor-associated antigen and at least anoth...
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, anemia, extramedullary ...
Metabolism, metabolites, and macrophages in cancer
Metabolism, metabolites, and macrophages in cancer
Tumour-associated macrophages (TAMs) are crucial components of the tumour microenvironment and play a significant role in ...
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients wit...
Novel target and treatment agents for natural killer/T-cell lymphoma
Novel target and treatment agents for natural killer/T-cell lymphoma
The rapidly increasing use of high-throughput screening had produced a plethora of expanding knowledge on the molecular ba...
Clinical development of mRNA therapies against solid tumors
Clinical development of mRNA therapies against solid tumors
The mRNA-based therapeutics have become the hot spot of biopharmaceutical industries in recent years. The landscape of thi...
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
Survival in multiple myeloma has improved significantly in recent years, especially in young patients. We reviewed the evo...
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
The receptor tyrosine kinases TAM family (TYRO3, AXL, and MERTK) are highly expressed in multiple forms of cancer cells an...
阅读更多
format_indent_increase